A team publishing in npj Viruses identified potent, broadly neutralizing antibodies that target both Marburg virus and the related Ravn virus. The antibodies neutralize multiple viral strains in vitro and showed protective activity in preclinical models, representing a rare advance against filoviruses beyond Ebola. Authors mapped antibody epitopes and demonstrated cross‑reactivity, supporting development paths for monoclonal therapeutics and design of pan‑filovirus immunogens. The discovery reopens therapeutic strategies for Marburg virus disease amid global concerns about emerging hemorrhagic fever threats. Developers of antiviral biologics and biodefense programs will view the antibodies as candidate leads for accelerated preclinical development and potential stockpiling partnerships.